(Q42997289)

12 November 2017

title

Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

Syria Laperche

1

1 reference

12 November 2017

Marie-Hélène Elghouzzi

2

1 reference

12 November 2017

Pascal Morel

3

1 reference

12 November 2017

Marianne Asso-Bonnet

4

1 reference

12 November 2017

Nadine Le Marrec

5

1 reference

12 November 2017

Annie Girault

6

1 reference

12 November 2017

Annabelle Servant-Delmas

7

1 reference

12 November 2017

Françoise Bouchardeau

8

1 reference

12 November 2017

Marie Deschaseaux

9

1 reference

12 November 2017

Yves Piquet

10

1 reference

12 November 2017

language of work or name

1 reference

1 December 2005

1 reference

12 November 2017

1 reference

12 November 2017

volume

45

1 reference

12 November 2017

issue

12

1 reference

12 November 2017

page(s)

1965-1972

1 reference

Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

International application of the incidence rate/window period model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

HCV screening in blood donations using RT-PCR in mini-pool: the experience in Spain after routine use for 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

HCV viral load in anti‐HCV‐reactive donors and infectivity for their recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Hepatitis C core antigen in Polish blood donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

HCV core antigen as an alternative to NAT to detect HCV viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

The UK blood transfusion service: over a (patent) barrel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription-mediated amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Sensitivity of HCV RNA and HIV RNA blood screening assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Acute HCV infection detected in a blood donor by NAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

HIV-1 and HCV infections among antibody-negative blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Acute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Efficacy of HCV core antigen detection during the preseroconversion period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

Structural biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00648.X

10.1111/J.1537-2995.2005.00648.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference